-
1
-
-
0033200188
-
Advances toward gene therapy for hemophilia at the millennium
-
Kaufman RJ. Advances toward gene therapy for hemophilia at the millennium. Hum Gene Ther 1999; 10: 2091-107.
-
(1999)
Hum Gene Ther
, vol.10
, pp. 2091-2107
-
-
Kaufman, R.J.1
-
2
-
-
84916617201
-
-
Pilot study of hemophilia treatment in the US National Heart, Lung and Blood Resources Studies
-
Department of Health and Human Services: National Heart LaBRS. Pilot study of hemophilia treatment in the US National Heart, Lung and Blood Resources Studies Vol. 3. 1972.
-
(1972)
National Heart LaBRS.
, vol.3
-
-
-
3
-
-
0028266130
-
A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group
-
Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White G 3rd, Lee M. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83: 2428-35.
-
(1994)
Blood
, vol.83
, pp. 2428-2435
-
-
Bray, G.L.1
Gomperts, E.D.2
Courter, S.3
Gruppo, R.4
Gordon, E.M.5
Manco-Johnson, M.6
Shapiro, A.7
Scheibel, E.8
White, G.9
Lee, M.10
-
4
-
-
0027473752
-
Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group
-
Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328: 453-9.
-
(1993)
N Engl J Med
, vol.328
, pp. 453-459
-
-
Lusher, J.M.1
Arkin, S.2
Abildgaard, C.F.3
Schwartz, R.S.4
-
5
-
-
77955492929
-
Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment
-
Mei B, Pan C, Jiang H, Tjandra H, Strauss J, Chen Y, Liu T, Zhang X, Severs J, Newgren J, Chen J, Gu JM, Subramanyam B, Fournel MA, Pierce GF, Murphy JE. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010; 116: 270-9.
-
(2010)
Blood
, vol.116
, pp. 270-279
-
-
Mei, B.1
Pan, C.2
Jiang, H.3
Tjandra, H.4
Strauss, J.5
Chen, Y.6
Liu, T.7
Zhang, X.8
Severs, J.9
Newgren, J.10
Chen, J.11
Gu, J.M.12
Subramanyam, B.13
Fournel, M.A.14
Pierce, G.F.15
Murphy, J.E.16
-
6
-
-
84897562467
-
Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias
-
Mancuso ME, Mannucci PM. Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias. Drug Des Devel Ther 2014; 8: 365-71.
-
(2014)
Drug Des Devel Ther
, vol.8
, pp. 365-371
-
-
Mancuso, M.E.1
Mannucci, P.M.2
-
7
-
-
84898028710
-
Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A
-
Coyle TE, Reding MT, Lin JC, Michaels LA, Shah A, Powell J. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost 2014; 12: 488-96.
-
(2014)
J Thromb Haemost
, vol.12
, pp. 488-496
-
-
Coyle, T.E.1
Reding, M.T.2
Lin, J.C.3
Michaels, L.A.4
Shah, A.5
Powell, J.6
-
8
-
-
0038383605
-
The epidemiology of inhibitors in haemophilia A: a systematic review
-
Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
-
(2003)
Haemophilia
, vol.9
, pp. 418-435
-
-
Wight, J.1
Paisley, S.2
-
9
-
-
84905861716
-
Promising coagulation factor VIII bypassing strategies for patients with haemophilia A
-
Duan X, Tang M, Zhang J, Yu H, Xu R. Promising coagulation factor VIII bypassing strategies for patients with haemophilia A. Blood Coagul Fibrinolysis 2014; 25: 539-52.
-
(2014)
Blood Coagul Fibrinolysis
, vol.25
, pp. 539-552
-
-
Duan, X.1
Tang, M.2
Zhang, J.3
Yu, H.4
Xu, R.5
-
10
-
-
10744231807
-
Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment
-
Yarovoi HV, Kufrin D, Eslin DE, Thornton MA, Haberichter SL, Shi Q, Zhu H, Camire R, Fakharzadeh SS, Kowalska MA, Wilcox DA, Sachais BS, Montgomery RR, Poncz M. Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment. Blood 2003; 102: 4006-13.
-
(2003)
Blood
, vol.102
, pp. 4006-4013
-
-
Yarovoi, H.V.1
Kufrin, D.2
Eslin, D.E.3
Thornton, M.A.4
Haberichter, S.L.5
Shi, Q.6
Zhu, H.7
Camire, R.8
Fakharzadeh, S.S.9
Kowalska, M.A.10
Wilcox, D.A.11
Sachais, B.S.12
Montgomery, R.R.13
Poncz, M.14
-
11
-
-
33745864802
-
Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies
-
Shi Q, Wilcox DA, Fahs SA, Weiler H, Wells CW, Cooley BC, Desai D, Morateck PA, Gorski J, Montgomery RR. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. J Clin Invest 2006; 116: 1974-82.
-
(2006)
J Clin Invest
, vol.116
, pp. 1974-1982
-
-
Shi, Q.1
Wilcox, D.A.2
Fahs, S.A.3
Weiler, H.4
Wells, C.W.5
Cooley, B.C.6
Desai, D.7
Morateck, P.A.8
Gorski, J.9
Montgomery, R.R.10
-
12
-
-
33846453333
-
Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A
-
Shi Q, Wilcox DA, Fahs SA, Fang J, Johnson BD, Du LM, Desai D, Montgomery RR. Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. J Thromb Haemost 2007; 5: 352-61.
-
(2007)
J Thromb Haemost
, vol.5
, pp. 352-361
-
-
Shi, Q.1
Wilcox, D.A.2
Fahs, S.A.3
Fang, J.4
Johnson, B.D.5
Du, L.M.6
Desai, D.7
Montgomery, R.R.8
-
13
-
-
45549109031
-
Platelet-delivered factor VIII provides limited resistance to anti-factor VIII inhibitors
-
Gewirtz J, Thornton MA, Rauova L, Poncz M. Platelet-delivered factor VIII provides limited resistance to anti-factor VIII inhibitors. J Thromb Haemost 2008; 6: 1160-6.
-
(2008)
J Thromb Haemost
, vol.6
, pp. 1160-1166
-
-
Gewirtz, J.1
Thornton, M.A.2
Rauova, L.3
Poncz, M.4
-
14
-
-
84905667071
-
In vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low MOI
-
Schroeder JA, Chen Y, Fang J, Wilcox DA, Shi Q. In vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low MOI. J Thromb Haemost 2014; 12: 1283-93.
-
(2014)
J Thromb Haemost
, vol.12
, pp. 1283-1293
-
-
Schroeder, J.A.1
Chen, Y.2
Fang, J.3
Wilcox, D.A.4
Shi, Q.5
-
15
-
-
51649110213
-
Analysis of the spatial and temporal characteristics of platelet-delivered factor VIII-based clots
-
Neyman M, Gewirtz J, Poncz M. Analysis of the spatial and temporal characteristics of platelet-delivered factor VIII-based clots. Blood 2008; 112: 1101-8.
-
(2008)
Blood
, vol.112
, pp. 1101-1108
-
-
Neyman, M.1
Gewirtz, J.2
Poncz, M.3
-
16
-
-
84878263829
-
Harnessing the platelet signaling network to produce an optimal hemostatic response
-
Brass LF, Tomaiuolo M, Stalker TJ. Harnessing the platelet signaling network to produce an optimal hemostatic response. Hematol Oncol Clin North Am 2013; 27: 381-409.
-
(2013)
Hematol Oncol Clin North Am
, vol.27
, pp. 381-409
-
-
Brass, L.F.1
Tomaiuolo, M.2
Stalker, T.J.3
-
17
-
-
0141456083
-
Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector
-
Scallan CD, Lillicrap D, Jiang H, Qian X, Patarroyo-White SL, Parker AE, Liu T, Vargas J, Nagy D, Powell SK, Wright JF, Turner PV, Tinlin SJ, Webster SE, McClelland A, Couto LB. Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector. Blood 2003; 102: 2031-7.
-
(2003)
Blood
, vol.102
, pp. 2031-2037
-
-
Scallan, C.D.1
Lillicrap, D.2
Jiang, H.3
Qian, X.4
Patarroyo-White, S.L.5
Parker, A.E.6
Liu, T.7
Vargas, J.8
Nagy, D.9
Powell, S.K.10
Wright, J.F.11
Turner, P.V.12
Tinlin, S.J.13
Webster, S.E.14
McClelland, A.15
Couto, L.B.16
-
18
-
-
73349120945
-
Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model
-
Sabatino DE, Freguia CF, Toso R, Santos A, Merricks EP, Kazazian HH Jr, Nichols TC, Camire RM, Arruda VR. Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model. Blood 2009; 114: 4562-5.
-
(2009)
Blood
, vol.114
, pp. 4562-4565
-
-
Sabatino, D.E.1
Freguia, C.F.2
Toso, R.3
Santos, A.4
Merricks, E.P.5
Kazazian Jr, H.H.6
Nichols, T.C.7
Camire, R.M.8
Arruda, V.R.9
-
19
-
-
84880427173
-
Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype
-
Siner JI, Iacobelli NP, Sabatino DE, Ivanciu L, Zhou S, Poncz M, Camire RM, Arruda VR. Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype. Blood 2013; 121: 4396-403.
-
(2013)
Blood
, vol.121
, pp. 4396-4403
-
-
Siner, J.I.1
Iacobelli, N.P.2
Sabatino, D.E.3
Ivanciu, L.4
Zhou, S.5
Poncz, M.6
Camire, R.M.7
Arruda, V.R.8
-
20
-
-
78650653228
-
In vivo efficacy of platelet-delivered, high specific activity factor VIII variants
-
Greene TK, Wang C, Hirsch JD, Zhai L, Gewirtz J, Thornton MA, Miao HZ, Pipe SW, Kaufman RJ, Camire RM, Arruda VR, Kowalska MA, Poncz M. In vivo efficacy of platelet-delivered, high specific activity factor VIII variants. Blood 2010; 116: 6114-22.
-
(2010)
Blood
, vol.116
, pp. 6114-6122
-
-
Greene, T.K.1
Wang, C.2
Hirsch, J.D.3
Zhai, L.4
Gewirtz, J.5
Thornton, M.A.6
Miao, H.Z.7
Pipe, S.W.8
Kaufman, R.J.9
Camire, R.M.10
Arruda, V.R.11
Kowalska, M.A.12
Poncz, M.13
-
21
-
-
0029996147
-
In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
-
Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-7.
-
(1996)
Science
, vol.272
, pp. 263-267
-
-
Naldini, L.1
Blomer, U.2
Gallay, P.3
Ory, D.4
Mulligan, R.5
Gage, F.H.6
Verma, I.M.7
Trono, D.8
-
22
-
-
0029011723
-
Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A
-
Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 119-21.
-
(1995)
Nat Genet
, vol.10
, pp. 119-121
-
-
Bi, L.1
Lawler, A.M.2
Antonarakis, S.E.3
High, K.A.4
Gearhart, J.D.5
Kazazian Jr, H.H.6
-
23
-
-
0037111573
-
Identification of distal regulatory regions in the human alpha IIb gene locus necessary for consistent, high-level megakaryocyte expression
-
Thornton MA, Zhang C, Kowalska MA, Poncz M. Identification of distal regulatory regions in the human alpha IIb gene locus necessary for consistent, high-level megakaryocyte expression. Blood 2002; 100: 3588-96.
-
(2002)
Blood
, vol.100
, pp. 3588-3596
-
-
Thornton, M.A.1
Zhang, C.2
Kowalska, M.A.3
Poncz, M.4
-
24
-
-
0141595894
-
Thrombus formation: direct real-time observation and digital analysis of thrombus assembly in a living mouse by confocal and widefield intravital microscopy
-
Celi A, Merrill-Skoloff G, Gross P, Falati S, Sim DS, Flaumenhaft R, Furie BC, Furie B. Thrombus formation: direct real-time observation and digital analysis of thrombus assembly in a living mouse by confocal and widefield intravital microscopy. J Thromb Haemost 2003; 1: 60-8.
-
(2003)
J Thromb Haemost
, vol.1
, pp. 60-68
-
-
Celi, A.1
Merrill-Skoloff, G.2
Gross, P.3
Falati, S.4
Sim, D.S.5
Flaumenhaft, R.6
Furie, B.C.7
Furie, B.8
-
25
-
-
0027237331
-
Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production
-
Lynch CM, Israel DI, Kaufman RJ, Miller AD. Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum Gene Ther 1993; 4: 259-72.
-
(1993)
Hum Gene Ther
, vol.4
, pp. 259-272
-
-
Lynch, C.M.1
Israel, D.I.2
Kaufman, R.J.3
Miller, A.D.4
-
26
-
-
0036301504
-
Expression of factor VIII in recombinant and transgenic systems
-
Soukharev S, Hammond D, Ananyeva NM, Anderson JA, Hauser CA, Pipe S, Saenko EL. Expression of factor VIII in recombinant and transgenic systems. Blood Cells Mol Dis 2002; 28: 234-48.
-
(2002)
Blood Cells Mol Dis
, vol.28
, pp. 234-248
-
-
Soukharev, S.1
Hammond, D.2
Ananyeva, N.M.3
Anderson, J.A.4
Hauser, C.A.5
Pipe, S.6
Saenko, E.L.7
-
27
-
-
57449092891
-
Antioxidants reduce endoplasmic reticulum stress and improve protein secretion
-
Malhotra JD, Miao H, Zhang K, Wolfson A, Pennathur S, Pipe SW, Kaufman RJ. Antioxidants reduce endoplasmic reticulum stress and improve protein secretion. Proc Natl Acad Sci USA 2008; 105: 18525-30.
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, pp. 18525-18530
-
-
Malhotra, J.D.1
Miao, H.2
Zhang, K.3
Wolfson, A.4
Pennathur, S.5
Pipe, S.W.6
Kaufman, R.J.7
-
28
-
-
78649989718
-
Animal Models Subcommittee of the Scientific and Standardization Committee of the ISTH. Towards a standardization of the murine tail bleeding model
-
Greene TK, Schiviz A, Hoellriegl W, Poncz M, Muchitsch EM. Animal Models Subcommittee of the Scientific and Standardization Committee of the ISTH. Towards a standardization of the murine tail bleeding model. J Thromb Haemost 2010; 8: 2820-2.
-
(2010)
J Thromb Haemost
, vol.8
, pp. 2820-2822
-
-
Greene, T.K.1
Schiviz, A.2
Hoellriegl, W.3
Poncz, M.4
Muchitsch, E.M.5
-
29
-
-
1842852173
-
Plateletcrit, mean platelet volume, platelet distribution width: its expected values and correlation with parallel red blood cell parameters
-
Wiwanitkit V. Plateletcrit, mean platelet volume, platelet distribution width: its expected values and correlation with parallel red blood cell parameters. Clin Appl Thromb Hemost 2004; 10: 175-8.
-
(2004)
Clin Appl Thromb Hemost
, vol.10
, pp. 175-178
-
-
Wiwanitkit, V.1
-
30
-
-
84893419411
-
Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A
-
Du LM, Nurden P, Nurden AT, Nichols TC, Bellinger DA, Jensen ES, Haberichter SL, Merricks E, Raymer RA, Fang J, Koukouritaki SB, Jacobi PM, Hawkins TB, Cornetta K, Shi Q, Wilcox DA. Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A. Nat Commun 2013; 4: 2773.
-
(2013)
Nat Commun
, vol.4
, pp. 2773
-
-
Du, L.M.1
Nurden, P.2
Nurden, A.T.3
Nichols, T.C.4
Bellinger, D.A.5
Jensen, E.S.6
Haberichter, S.L.7
Merricks, E.8
Raymer, R.A.9
Fang, J.10
Koukouritaki, S.B.11
Jacobi, P.M.12
Hawkins, T.B.13
Cornetta, K.14
Shi, Q.15
Wilcox, D.A.16
-
31
-
-
0842277797
-
Bleeding complications after hematopoietic stem cell transplantation
-
Pihusch M. Bleeding complications after hematopoietic stem cell transplantation. Semin Hematol 2004; 41: 93-100.
-
(2004)
Semin Hematol
, vol.41
, pp. 93-100
-
-
Pihusch, M.1
-
32
-
-
0037325163
-
Structure and function of the factor VIII gene and protein
-
Thompson AR. Structure and function of the factor VIII gene and protein. Semin Thromb Hemost 2003; 29: 11-22.
-
(2003)
Semin Thromb Hemost
, vol.29
, pp. 11-22
-
-
Thompson, A.R.1
-
33
-
-
20444417088
-
Intracellular interaction of von Willebrand factor and factor VIII depends on cellular context: lessons from platelet-expressed factor VIII
-
Yarovoi H, Nurden AT, Montgomery RR, Nurden P, Poncz M. Intracellular interaction of von Willebrand factor and factor VIII depends on cellular context: lessons from platelet-expressed factor VIII. Blood 2005; 105: 4674-6.
-
(2005)
Blood
, vol.105
, pp. 4674-4676
-
-
Yarovoi, H.1
Nurden, A.T.2
Montgomery, R.R.3
Nurden, P.4
Poncz, M.5
-
34
-
-
0030664471
-
Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa
-
Pipe SW, Kaufman RJ. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc Natl Acad Sci USA 1997; 94: 11851-6.
-
(1997)
Proc Natl Acad Sci USA
, vol.94
, pp. 11851-11856
-
-
Pipe, S.W.1
Kaufman, R.J.2
-
35
-
-
0022049305
-
Biochemistry of alpha granule proteins
-
Holt JC, Niewiarowski S. Biochemistry of alpha granule proteins. Semin Hematol 1985; 22: 151-63.
-
(1985)
Semin Hematol
, vol.22
, pp. 151-163
-
-
Holt, J.C.1
Niewiarowski, S.2
-
36
-
-
0019819351
-
Gray platelet syndrome: alpha-granule deficiency. Its influence on platelet function
-
Levy-Toledano S, Caen JP, Breton-Gorius J, Rendu F, Cywiner-Golenzer C, Dupuy E, Legrand Y, Maclouf J. Gray platelet syndrome: alpha-granule deficiency. Its influence on platelet function. J Lab Clin Med 1981; 98: 831-48.
-
(1981)
J Lab Clin Med
, vol.98
, pp. 831-848
-
-
Levy-Toledano, S.1
Caen, J.P.2
Breton-Gorius, J.3
Rendu, F.4
Cywiner-Golenzer, C.5
Dupuy, E.6
Legrand, Y.7
Maclouf, J.8
-
37
-
-
0025743588
-
The platelet open canalicular system: a final common pathway
-
Escolar G, White JG. The platelet open canalicular system: a final common pathway. Blood Cells 1991; 17: 467-85.
-
(1991)
Blood Cells
, vol.17
, pp. 467-485
-
-
Escolar, G.1
White, J.G.2
|